Legend Biotech Corp: Form 6-K Summary (Period Ended June 30, 2026)
Business Context and Reporting Period
This Form 6-K reports the unaudited interim condensed consolidated financial results for Legend Biotech Corporation for the three and six months ended June 30, 2026. Legend is a global biopharmaceutical company focused on cell therapies, primarily driven by its collaboration with Janssen Biotech (Johnson & Johnson) for the commercialization of CARVYKTI (ciltacabtagene autoleucel) for multiple myeloma. The report includes financial statements, Management's Discussion and Analysis (MD&A), and a supplemental risk factor.
Key Financial Metrics
| Metric (Dollars in millions) | 3 Months Ended Jun 30, 2026 | 6 Months Ended Jun 30, 2026 |
|---|---|---|
| Total Revenue | $387.5 | $692.6 |
| Net Income (Loss) | $33.2 | $(21.1) |
| Operating Income (Loss) | $57.7 | $7.9 |
| Adjusted Net Income (Non-IFRS) | $63.1 | $52.8 |
| Cash and Cash Equivalents | $672.9 (as of Jun 30, 2026) | $672.9 (as of Jun 30, 2026) |
| Time Deposits | $291.7 (as of Jun 30, 2026) | $291.7 (as of Jun 30, 2026) |
| Total Liquidity (Cash + Time Deposits) | $964.6 | $964.6 |
| Collaboration Interest-Bearing Advanced Funding | $156.4 (Current Liability) | $156.4 (Current Liability) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 52% year-over-year (YoY) for the three months ended June 30, 2026 ($387.5M vs. $255.1M) and 54% for the six months ($692.6M vs. $450.1M). This was driven by a 48% increase in collaboration revenue from CARVYKTI sales and a 74% increase in license revenue, largely due to $56.0M in milestones achieved under the Janssen Agreement.
- Profitability Turnaround: The company reported a net income of $33.2M for the quarter, a significant improvement from a net loss of $125.4M in the same period in 2025. For the six months, the net loss narrowed significantly to $21.1M from $226.4M in the prior year.
- Foreign Exchange Impact: Other expense, net, improved dramatically from a loss of $108.1M in Q2 2025 to $2.0M in Q2 2026, primarily due to a reduction in unrealized foreign currency exchange losses.
- Capital Raise: In June 2026, Legend completed a public offering of 7.7 million ADSs, raising net proceeds of approximately $212.4 million.
- Debt Reduction: The company reduced its collaboration advanced funding principal balance by $170.8 million during the six-month period through offsetting with pre-tax profit receivables and repayments.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes cash, cash equivalents, and time deposits of approximately $965 million, combined with expected operating cash flows, are sufficient to meet operational and loan repayment needs for at least the next 12 months.
- Business Highlights: CARVYKTI net trade sales increased 50% in Q2 2026 to approximately $657 million. The company expanded availability to 348 global sites and 19 markets. Clinical proof-of-concept was achieved for LB2501, an investigational in vivo CAR-T therapy.
- Risks and Contingencies:
- Tariffs: While current pharmaceutical tariffs do not materially impact operations, potential future tariffs on pharmaceutical ingredients could increase costs.
- Tax Uncertainty: The company is negotiating an advance pricing agreement with the Chinese Tax Authority; final outcomes may differ materially from current accruals.
- Debt Recoupment: The $156.4 million in collaboration interest-bearing advanced funding from Janssen is classified as a current liability, as it is expected to be recouped by Janssen within the next 12 months from pre-tax profits.
- Foreign Exchange: Significant fluctuations in the RMB against the USD could negatively impact reported earnings, though the company currently has no hedging transactions.
Key Facts for Investor Verification
- Revenue Composition: Verify the sustainability of collaboration revenue growth, which accounts for the vast majority of total revenue ($326.1M in Q2 2026).
- Non-IFRS Adjustments: Review the reconciliation of Adjusted Net Income ($63.1M for Q2) to GAAP/IFRS Net Income ($33.2M), noting the significant impact of unrealized foreign exchange losses and share-based compensation.
- Debt Structure: Confirm the terms and repayment schedule of the $156.4 million Janssen advanced funding, which is due within 12 months and serviced by future collaboration profits.
- Cash Flow Usage: Note that despite profitability in Q2, net cash used in operating activities for the six months was $106.0 million, driven by working capital changes and prepayments.
- Regulatory Status: Monitor the status of the advance pricing agreement with Chinese tax authorities and any potential changes in U.S. tariff policies affecting imported pharmaceutical ingredients.